Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Boston biotech Acetylon being acquired by Celgene

By , Globe Staff

Privately held Boston biotech company Acetylon Pharmaceuticals Inc., which is developing drugs to treat blood cancer and other diseases.

Bluebird shares soar 17 percent on multiple myeloma trial

By Robert Weisman , Globe Staff

The Cambridge biotech reported encouraging results from an early-stage study of its experimental cancer immunotherapy.

Cambridge biotech’s cancer therapy trial has promising results

By , Globe Staff

Bluebird Bio said its cancer immunotherapy worked in seven of nine multiple myeloma patients who received it in an early-stage trial.

Boston startup hopes to use bacteria to treat autism

By Robert Weisman , Globe Staff

A Boston venture capital firm is helping to launch a local startup that seeks to harness bacteria from the gut to treat diseases such as autism.